Tomahawk, WI 10/01/2014 (Basicsmedia) – Sarepta Therapeutics Inc. (NASDAQ:SRPT) is more than ready to provide its Ebola Drug if called upon by health officials. Appearing on an interview on CNBC, CEO, Chris Garabedian, reiterated that the company has enough stock to handle up to 100 cases at the moment.

The announcement that Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s drug has a success rate of between 60% and 80% on animals comes as a huge relief for the World Health Organization, which has been pushing for the development of cures.

“[…] what we hope to do with the drug samples we have available now is to make sure we get as much information about how our drug works in actual patients infected with Ebola. All of it in Monkey suggest it really impacts survival that it is safe in healthy volunteers. So we want to get much information about the technology.”

Sarepta Therapeutics Inc. (NASDAQ:SRPT) claims that minimal resources continues to be the biggest impediment in ramping up production that should see the availability of more doses. There are currently no approved drugs for Ebola meaning Sarepta stands to gain a great deal, should its drug be approved by the FDA and taken over by the WHO for treatment of Ebola cases in West Africa.

Ebola outbreak has caused pharmaceutical companies that are currently developing Ebola treatment to spike in the market as analysts remain optimistic about the space in terms of monetary returns of sales. The CEO also reiterated that costs and revenue will only be’ determined once a request is’ tabled from the relevant agencies in need of the drug.

“Yes we need more funding to take the drug material that we have currently, to convert that into upwards of 100 more courses of therapy or more. To be able to ramp up to 1000 of doses, we would require a larger investment and more time and that could take upwards of a year or more, to be able to generate enough doses to treat 1000 patients,” said Mr. Garabedian.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.